Technology | May 27, 2014

EkoSonic System Receives FDA Clearance for Treatment of Pulmonary Embolism

May 27, 2014 — Ekos Corp. announced the U.S. Food and Drug Administration (FDA) has cleared the EkoSonic endovascular system for the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism (PE).

The Ekos ultrasonic devices are designed to gently accelerate the penetration of thrombolytic agents into thrombus, providing high levels of lysis. Ekos is the only minimally invasive endovascular therapy on the market that has been FDA-cleared for the treatment of PE.

PE occurs in approximately 600,000 patients in the United States, causing or contributing to 200,000 deaths each year. PE is also said to cause or contribute to 15 percent of all hospital deaths. Samuel Z. Goldhaber, M.D., professor of medicine, Harvard Medical School, director, Thrombosis Research Group, Brigham and Woman’s Hospital, said, “The Ekos clinical data established that patients stricken with a life-threatening pulmonary embolism can be successfully and safely treated with the EkoSonic system. This is the first FDA-cleared treatment option for PE since the approval of the drug tPA in 1990.”

“Interventional radiologists, cardiologists, cardiothoracic and vascular surgeons at leading institutions around the world use our system to provide faster, safer and more complete dissolution of thrombus,” said Matt Stupfel, general manager of Ekos. “We are proud to have completed the world’s only randomized controlled trial (ULTIMA) and the largest prospective single-arm trial (SEATTLE II) on the safety and effectiveness of Ekos therapy in the treatment of PE. The positive outcomes of those trials, combined with our expanded indication, will allow a better standard of care for thousands of patients who suffer from PE.”

In January 2014, the outcomes of ULTIMA were published in American Heart Association’s journal Circulation. The trial demonstrated that for PE patients at intermediate risk of adverse events, Ekos treatment was clinically superior to anticoagulation with heparin alone in reversing right ventricular dilation at 24 hours, without an increase in bleeding complications.

Following ULTIMA, the results of SEATTLE II, the prospective single-arm multicenter trial of 150 patients, were released at this year’s American College of Cardiology (ACC) annual meeting. The SEATTLE II trial demonstrated that ultrasound-facilitated catheter-directed low-dose fibrinolysis for acute PE minimizes the risk of intracranial hemorrhage, improves RV function and decreases pulmonary hypertension.

For more information:

Related Content

Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system. #TCT2020 #TCTconnect

Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system.

News | Pulmonary Embolism | October 23, 2020
October 23, 2020 —  Positive results were reported on the first 230 patients enrolled in its FLASH study, a real worl
Smokers Have More Pulmonary Emboli, Leading to Higher Hospital Readmission Rates

Image courtesy of the American Heart Association

News | Pulmonary Embolism | October 18, 2019
Patients with lung blood clots who smoke are more likely to be readmitted for lung blood clots than nonsmokers,...
Aidoc Announces CE Mark for AI-based Pulmonary Embolism Workflow Tool
News | Pulmonary Embolism | March 04, 2019
Artificial intelligence (AI) radiology solution provider Aidoc announced the commercial release of its CE-marked...
First Balloon Pulmonary Angioplasty for Chronic Pulmonary Embolism Performed in Illinois
News | Pulmonary Embolism | October 23, 2018
Daniel J. Schimmel, Jr., M.D., MS, a cardiologist at Northwestern Memorial Hospital, recently performed the first...
Xarelto Associated With Reduced Hospital Time and Costs for Low-risk PE Patients
News | Pulmonary Embolism | June 29, 2018
Results from the MERCURY PE study showed that low-risk pulmonary embolism (PE) patients treated with Xarelto (...
Novel Way to Treat Blood Clots in Lungs, pulmonary embolism, Found Safe and Effective. #SCAI, #SCAI2018
News | Pulmonary Embolism | May 11, 2018
Results of the FlowTriever Pulmonary Embolectomy (FLARE) study were presented as late-breaking clinical science at the...
Technology | Pulmonary Embolism | March 01, 2017
March 1, 2017 — BTG plc announced U.S.
Pulmonary embolism, toshiba

A pulmonary embolism visualized on a CTA scan using SureSubtraction software on a Toshiba Aquilion One Vision CT scanner. 

Feature | Pulmonary Embolism | March 28, 2016 | Alain T. Drooz, M.D., FSVM, and David J. Spinosa, M.D.
Acute pulmonary embolism (PE) can pose a major treatment quandary for clinicians.
Ekos for PE

The Ekos catheter was recently cleared by the FDA to aid in infusion and in breaking down pulmonary emboli faster than traditional lytic treatment alone.

Feature | Pulmonary Embolism | October 03, 2014 | James M. McCabe, M.D., FACC, University of Washington, Seattle
Acute intermediate-risk pulmonary emboli (PE) in normotensive patients with right ventricle dysfunction present the...